Form 8-K - Current report:
SEC Accession No. 0001193125-25-273269
Filing Date
2025-11-10
Accepted
2025-11-10 07:32:53
Documents
13
Period of Report
2025-11-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d57756d8k.htm   iXBRL 8-K 36502
2 EX-99.1 d57756dex991.htm EX-99.1 20107
  Complete submission text file 0001193125-25-273269.txt   178312

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lyel-20251106.xsd EX-101.SCH 2843
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20251106_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20251106_pre.xml EX-101.PRE 10807
15 EXTRACTED XBRL INSTANCE DOCUMENT d57756d8k_htm.xml XML 3508
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 251464357
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)